Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts

🇨🇳 Article en anglais

China’s edge in fast, cost-effective early clinical trials has propelled its emergence as a global biopharmaceutical powerhouse, but there is a risk that the United States could take steps to curb that advantage, according to analysts. US lawmakers and officials at the Food and Drug Administration (FDA) have raised the alarm about America

Read the original article

Source : South China Morning Post. Le Fil Indépendant cite et lie cet article ; il n'en est ni l'auteur ni l'éditeur.